NanGenex, a Hungarian company that uses its own technology to synthesize nano-particles, is currently testing a new technology that enhances the absorption of three hypertension therapy drugs and is planning to release it in three years after conducting tests on animals, CEO Gábor Heltovics told MTI Thursday.
The technology, called NanoActive, increases the responsiveness of the drugs from the original 120 minutes to 30-45 minutes.
NanGenex is currently seeking business partners to conduct further experiments.
The three hypertension drugs are original products of foreign drug makers, also distributed in Hungary. The products have global annual turnover of over USD 1bn each. (MTI-ECONEWS)